Special Instructions
If you have questions, please call 800-533-1037 (HLA customer service) for assistance selecting the proper HLA test for the patient.
Expected Turnaround Time
3 - 7 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Related Documents
Specimen Requirements
Specimen
Whole blood
Volume
7 mL
Minimum Volume
3 mL
Container
Lavender-top (EDTA) tube
Storage Instructions
Maintain specimen at ambient temperature; protect from extreme heat or cold. Do not freeze.
Causes for Rejection
Hemolyzed; clotted specimen
Test Details
Use
Rheumatoid arthritis (RA) is a chronic autoimmune disease that primarily affects the joints. Worldwide, the pervalence ranges between 0.5 to 1 percent and genetic factors play a role in RA risk, severity, and progression. The most important gene conferring risk for Anti-Citrullinated Protein Antibody positive (ACPA+) RA resides in the class II major histocompatibility complex (MHC) at the HLA-DRB1 locus. The HLA-DRB1 alleles that predispose to RA are the DRB1*04:01, *04:04, *04:05, *04:08, *01:01, *01:02, *09:01, *10:01 and *14:02 alleles, most of which possess a shared epitope (SE). These alleles increase the risk of RA in all populations, but the degree of predisposition may vary with different populations.
Limitations
This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.
|
This test was developed |
|
This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration. |
Methodology
HLA results were obtained using massively parallel sequencing (also called Next-generation sequencing). Supplemental procedures based on sequence-based typing (SBT), sequence-specific oligonucleotide probes (SSOP), and sequence-specific primers (SSP) may be used as needed to obtain the required resolution. If you have questions, please call 800-533-1037 (HLA customer service) for assistance.
|
HLA results were obtained using massively parallel sequencing (also called Next |
|
HLA results were obtained using massively parallel sequencing (also called Next-generation sequencing). Supplemental procedures based on sequence-based typing (SBT), sequence-specific oligonucleotide probes (SSOP), and sequence-specific primers (SSP) may be used as needed to obtain the required resolution. If you have questions, please call 800-533-1037 (HLA customer service) for assistance. |
References
Kampstra ASB, Toes REM. HLA class II and rheumatoid arthritis: the bumpy road of revelation. Immunogenetics. 2017 Aug;69(8-9):597-603.28695293
Klareskog L, Catrina AL, Paget S. Rheumatoid arthritis. Lancet. 2009 Feb;373(9664):659-672.19157532
Kochi Y, Suzuki A, Yamamoto K. Genetic basis of rheumatoid arthritis: a current review. Biochem Biophys Res Commun. 2014 Sep 19;452(2):254-62.25078624
LOINC® Map
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf